Scholarlink

<p>This study aimed to evaluate the prognostic value of lesion-specific and proximal 40 mm pericoronary adipose tissue attenuation (PCATa) in predicting major adverse cardiovascular events (MACE) in patients with ischemic heart disease presenting with angina pectoris and to compare their predictive performance. This retrospective study included 213 patients with ≥ 50% coronary artery stenosis who underwent coronary computed tomography angiography and digital subtraction angiography between January 2020 and August 2023. MACE was assessed over a median follow-up period of 15 months. Cox proportional hazards models were used to identify MACE risk factors, and the incremental predictive value of PCATa was evaluated using the C-index and global Chi-square statistics. MACE occurred in 72 patients (33.80%). The proximal 40&#xa0;mm PCATa (LAD: HR = 1.041, LCX: HR = 1.046, RCA: HR = 1.043; all <i>P</i> &lt; 0.01) and lesion-specific PCATa (HR = 1.048, <i>P</i> = 0.001) were independent predictors of MACE, and their prognostic performance was comparable. In the secondary endpoint analysis, defined as a composite of all-cause mortality, sudden cardiac death, and acute myocardial infarction, only elevated RCA-PCATa (HR = 1.084, 95% CI: 1.026–1.146, <i>P</i> = 0.004) was independently associated with adverse outcomes. Risk stratification models integrating PCATa cutoff values and angina status demonstrated robust predictive ability for MACE. Incorporating PCATa into clinical risk models significantly improved the C-index and global Chi-square values for MACE prediction (all <i>P</i> &lt; 0.01). These findings suggest that incorporating PCATa to clinical models significantly improves prognostic accuracy, with comparable performance between proximal and lesion-specific PCATa, while RCA-PCATa may provide superior prognostic value for the most severe cardiovascular outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prognostic value of lesion-specific and proximal coronary segment pericoronary adipose tissue CT Attenuation in ischemic heart disease with angina pectoris

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月24日

查看全文
  • Lingli Wang,
  • Wenfeng He,
  • Siyu Jiang,
  • Kaixiang Su,
  • Yuqing Tang,
  • Caifeng Pang,
  • Xinyue Chen,
  • Xi Liu,
  • Rui Li

摘要

This study aimed to evaluate the prognostic value of lesion-specific and proximal 40 mm pericoronary adipose tissue attenuation (PCATa) in predicting major adverse cardiovascular events (MACE) in patients with ischemic heart disease presenting with angina pectoris and to compare their predictive performance. This retrospective study included 213 patients with ≥ 50% coronary artery stenosis who underwent coronary computed tomography angiography and digital subtraction angiography between January 2020 and August 2023. MACE was assessed over a median follow-up period of 15 months. Cox proportional hazards models were used to identify MACE risk factors, and the incremental predictive value of PCATa was evaluated using the C-index and global Chi-square statistics. MACE occurred in 72 patients (33.80%). The proximal 40 mm PCATa (LAD: HR = 1.041, LCX: HR = 1.046, RCA: HR = 1.043; all P < 0.01) and lesion-specific PCATa (HR = 1.048, P = 0.001) were independent predictors of MACE, and their prognostic performance was comparable. In the secondary endpoint analysis, defined as a composite of all-cause mortality, sudden cardiac death, and acute myocardial infarction, only elevated RCA-PCATa (HR = 1.084, 95% CI: 1.026–1.146, P = 0.004) was independently associated with adverse outcomes. Risk stratification models integrating PCATa cutoff values and angina status demonstrated robust predictive ability for MACE. Incorporating PCATa into clinical risk models significantly improved the C-index and global Chi-square values for MACE prediction (all P < 0.01). These findings suggest that incorporating PCATa to clinical models significantly improves prognostic accuracy, with comparable performance between proximal and lesion-specific PCATa, while RCA-PCATa may provide superior prognostic value for the most severe cardiovascular outcomes.